BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)

February 29 | 2024

Below is a summary of the resolution passed. Complete resolution can be found on the company's website. The resolution was passed with the required majority.

Changes to the Board of directors

At the Extraordinary General Meeting of 2cureX AB (publ) today, 29 February 2024, it was decided to elect Grith Hagel as a new board member.

This election a part of a strategic initiative as 2cureX refines its strategy to facilitate the implementation of IndiTreat® testing across individual hospitals. Such a move towards decentralization necessitates an enhancement of the company's expertise in technical and regulatory areas. Grith Hagel is poised to significantly contribute to the integration and adoption of the IndiTreat® platform within cancer hospitals due to her background and expertise.

As a co-founder of 2cureX and previously of BioImage, a company that evolved from Novo Nordisk, where she had a pivotal role in establishing and managing a highly profitable partnership between BioImage and Amersham plc (presently GE Healthcare) showcases her capabilities. Moreover, Grith's contributions as an inventor with a comprehensive portfolio of issued patents, particularly those that offer substantial intellectual property protection for IndiTreat® in key global markets, underline her valuable asset to the company.

The Board of Directors hereafter consists of Tonny Bülow-Nielsen, Grith Hagel and Ole Thastrup.

Publication

The information was submitted for publication, through the agency of the contact persons set out below, at 16:00 CEST on February 29, 2024.

Malmö in February 2024

2cureX AB (publ)

Board of Directors

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the extraordinary general meeting in 2cureX AB, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB